How ESE is Funded
The following funding model has been deemed suitable for participating in EMA activities, acting in the interests of European patients, consumers and healthcare professionals. This evaluation was completed with reference to ESE funding for the 2024 financial year.
ESE is funded through a number of industry and non-industry sources:
- Membership – individual
- Membership – Corporate – See all our Corporate members
- Revenue generated by ESE owned journal ‘European Journal of Endocrinology’
- Revenue from industry into ECE and other educational programmes, principally through support of satellite sessions and exhibition stands and unrestricted educational grants in support of postgraduate education
- Of the revenue into ESE in the 2024 accounts 39.17% was provided by industry.
- The highest contribution from a single company represented 13.11% of the industry revenue and 5.14% of ESE revenue overall.
The list of all industry and non-industry revenue sources in 2024 are listed below.
- Amolyt Pharma
- AndroLabs
- Ascendis Pharma
- Astellas
- Biocartis
- Bioscientifica
- Blueprint Genetics
- BridgeBio
- Camurus AB
- Capitainer AB
- Chiesi
- Clarius Mobile Health
- Clinical Endocrinology Trust
- COR2ED (for Kyowa Kirin)
- Crinetics Pharmaceuticals Inc.
- Cushing's Support and Research Foundation
- Endocrine Society
- Horizon Therapeutics
- HRA Pharma Rare Diseases
- Inozyme Pharma
- Ipsen
- Kyowa kirin
- McCann Health (for Horizon/Amgen)
- Neurocrine Biosciences/Diurnal Ltd
- Novo Nordisk Health Care AG
- Pfizer Ltd
- Protherics Medicines Devel
- Recordati Rare Diseases AG
- Rhythm Pharmaceuticals
- SERB Pharmaceuticals
- Soleno Therapeutics
- Sparrow Pharma
- Takeda Pharmaceuticals International AG
- Uni Pharma Kleon Tsetis
- Wisepress
